Drug General Information
Drug ID
D09XMX
Former ID
DNCL003356
Drug Name
SaxaDapa FDC
Indication Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] Phase 3 [530967], [531182]
Company
AstraZeneca
Target and Pathway
Target(s) Dipeptidyl peptidase IV Target Info Modulator [530967], [531182]
Sodium/glucose cotransporter 2 Target Info Modulator [530967], [531182]
KEGG Pathway Protein digestion and absorption
NetPath Pathway IL2 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
Reactome Hexose transport
Na+-dependent glucose transporters
Inositol transporters
WikiPathways NRF2 pathway
References
Ref 530967Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
Ref 531182The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010 Nov;12(11):1004-12.
Ref 530967Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
Ref 531182The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010 Nov;12(11):1004-12.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.